High p95HER2/HER2 Ratio | Integrated Oncology

LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Date Posted

Sun, 03/18/2018 - 12:00

Publication

Clinical Cancer Research

Poster Title

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Author

Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Martine Antoine, Alvaro Moreno Aspitia,Winston Tan, John Winslow, Christos J. Petropoulos, Ahmed Chenna, Michael Bates, Jodi Marie Weidler, Weidong Huang, Amylou Dueck, and Edith A. Perez

PDF

2018_ccr_p95_in_finher.pdf553.47 KB

Type

Article